Merrimack begins Phase II trial of MM-121 to treat patients with heregulin positive NSCLC

US-based Merrimack Pharmaceuticals has started a Phase II clinical trial of its fully human monoclonal antibody, MM-121, in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone to treat patients with heregulin positive, local…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news